A Move To Shift Part B Rx Into Part D Would Anger Oncologists, Cancer Patients

If the administration were to propose shifting drugs covered by Medicare Part B into the Part D drug reimbursement system, the move would spark a blitz of opposition from cancer doctors and patients, and hospitals might also push back hard if the policy were accompanied by changes to the 340B drug discount program, lobbyists say. There has been a swirl of rumors in the past week that the administration is poised to propose some sort of drug price policy, lobbyists...